Clinical trial
Dose Escalation Study to Assess the Safety and Tolerability of Incremental Doses of QAB149 in Adults With Mild-to-moderate Chronic Obstructive Pulmonary Disease (COPD)
NCT00129831 is registered in ClinicalTrials.gov with Novartis as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Dose Escalation Study to Assess the Safety and Tolerability of Incremental Doses of QAB149 in Adults With Mild-to-moderate Chronic Obstructive Pulmonary Disease (COPD)
- Lead sponsor
- Novartis
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- September 30, 2004
- Completion date
- September 30, 2005
- Enrollment
- 6 (actual)
- Sites
- 2
Conditions
As the registry lists them; a condition with its own page is linked.
copd